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The telomerase reverse transcriptase (TERT) gene is highly expressed in stem cells and 
silenced upon differentiation. Cancer cells can attain immortality by activating TERT to maintain 
telomere length and telomerase activity, which is a crucial step of tumorigenesis. Two somatic 
mutations in the TERT promoter (C228T; C250T) have been identified as gain-of-function 
mutations that promote transcriptional activation of TERT in multiple cancers, such as melanoma 
and glioblastoma. A recent study investigating TERT promoter mutations in ovarian carcinomas 
found C228T and C250T mutations in 15.9% of clear cell carcinomas. However, it is unknown 
whether these mutations are frequent in other ovarian cancer subtypes, in particular, sex cord-
stromal tumors including adult granulosa cell tumors. We performed whole genome sequencing 
on ten adult granulosa cell tumors with matched normal blood and identified a TERT C228T 
promoter mutation in 50% of tumors. We found that adult granulosa cell tumors with 
mutated TERT promoter have increased expression of TERT mRNA and exhibited significantly 
longer telomeres compared to those with wild-type TERT promoter. Extension cohort analysis 
using allelic discrimination revealed the TERT C228T mutation in 51 of 229 primary adult 
granulosa cell tumors (22%), 24 of 58 recurrent adult granulosa cell tumors (41%), and 1 of 22 
other sex cord-stromal tumors (5%). There was a significant difference in overall survival 
between patients with TERT C228T promoter mutation in the primary tumors and those without 
it (p = 0.00253, log rank test). In seven adult granulosa cell tumors, we found the TERT 
C228T mutation present in recurrent tumors and absent in the corresponding primary tumor. Our 
data suggests that TERT C228T promoter mutations may have an important role in progression 
of adult granulosa cell tumors. 
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 Telomeres are conserved, repetitive (TTAGGG) DNA-protein complexes that are added 
to the ends of chromosomes by the enzyme telomerase to prevent DNA damage and maintain 
replicative potential1. Telomere attrition during DNA replication induces genomic instability that 
can result in tumorigenesis2. Telomerase consists of a catalytic protein subunit known as 
telomerase reverse transcriptase (TERT) and a functional RNA called telomerase RNA 
component (TERC)3. TERT is highly expressed in stem cells and is silenced upon differentiation 
in somatic cells4. Most cancer cells attain proliferative immortality by upregulating the TERT 
gene to maintain telomere length and telomerase activity5. The known mechanisms of telomerase 
activation include mutations in the TERT promoter, TERT gene amplification, CpG methylation 
at the TERT promoter, changes in alternative splicing of TERT pre-mRNA and upregulation of 
transcriptional activators6. Approximately 90% of cancers express TERT, while the remaining 
10-15% of cancers maintain their telomere length through a telomerase-independent method 
called alternative lengthening of telomeres7. 
 TERT promoter mutations were first reported in familial melanoma and subsequently in 
sporadic melanoma8,9. There are two hot-spot TERT promoter mutations, C228T and C250T, 
each generates an identical 11 base pair sequence containing a consensus binding motif for ETS 
transcription factors, and functions as either a transcriptional activator or repressor to regulate 
telomerase expression8,9. These two mutations are implicated in the activation of telomerase in 
other malignances such as central nervous system tumors, hepatocellular carcinomas, bladder 
cancers and thyroid cancers10,11. A recent study on TERT promoter mutations in gynecological 
malignancies, including ovarian and uterine carcinomas, reported TERT hot-spot mutations in 
15.9% of ovarian clear cell carcinomas12. However, it is unknown whether TERT promoter 
mutations are frequent in sex cord-stromal tumors, including adult granulosa cell tumors. In this 
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study, we evaluated the biological and clinical significance of TERT promoter mutations, 
specifically C228T, in total of 251 primary ovarian sex cord-stromal tumors.  
 
Materials and Methods 
Patient cohort description 
Adult granulosa cell tumors  (n = 303) were collected from Helsinki University Hospital 
(Helsinki, Finland; n = 142), Tübingen University Hospital (Tübingen, Germany; n =49), 
Massachusetts General Hospital (Boston, USA; n = 41), Netherlands Cancer Institute 
(Amsterdam, Netherlands; n = 30), OvCaRe Gynecological Tumor Bank, (Vancouver, Canada; n 
= 20), the Jikei University School of Medicine (Tokyo, Japan; n = 14) and Referral Center for 
Gynecopathology (Mannheim, Germany; n = 7). The other sex cord-stromal tumors were 
collected from Vancouver General Hospital (Vancouver, Canada; n = 22). The respective 
institutional research ethics board approved the waiver for patient consent. The British Columbia 
Cancer Agency and the University of British Columbia Research Ethics Boards approved the 
overall project methods. All cases were reviewed by at least one of the following expert 
pathologists (C.B.G., F.K., H.M.H., A.N.K., R.B., H.L-C., B.T.C., L.H.) to confirm the diagnosis 
of the sex cord-stromal tumor. A FOXL2 C402G allelic discrimination assay was used to validate 
adult granulosa cell tumor diagnosis. Of the 229 primary adult granulosa cell tumors, 223 
harbored a heterozygous FOXL2 C402G mutation and 6 harbored a homozygous, and were 
considered molecularly defined adult granulosa cell tumor as previously described13. For the 
adult granulosa cell tumor sequencing cohort, tumors were reviewed from frozen material, by at 
least two expert gynecological pathologists (H.M.H., A.N.K., H.L.-C., and C.B.G.), and C.B.G. 
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approved the final selected cohort. All adult granulosa cell tumors sequenced were primary 
tumor samples. Each respective institution for Helsinki, Boston, Tübingen, Amsterdam, 
Mannheim, and Tokyo cases collected clinical follow-up data.   
Whole genome sequencing analysis of adult granulosa cell tumors 
A total of ten fresh-frozen adult granulosa cell tumor tissues with >80% tumor cellularity (based 
on frozen hematoxylin and eosin slide review) were selected for cryosectioning and DNA 
extraction. Patient tumor and normal blood samples were collected at diagnosis during standard-
of-care debulking surgery. DNA was extracted from matched normal (peripheral blood buffy 
coat) and tumor (frozen tissues) samples using QIAmp Blood and Tissue DNA (Qiagen, 
Mississauga, ON) and quantified using the Qubit Fluorometer with the dsDNA High Sensitivity 
Assay Kit (ThermoFisher Scientific, Canada). Whole genome sequencing was performed using 
Illumina HiSeq 2500 v4 chemistry (Illumina Inc., Hayward, CA) with the PCR-free protocol to 
eliminate PCR-induced bias and to improve coverage across the genome. Whole genome 
sequencing analysis was performed to identify somatic alterations in each case, including single 
nucleotide variants, small indels, copy number alterations and structural variants. For a full 
description of library construction and sequencing methods, please refer to Wang Y. K. et al., 
Nature Genetics, 201714.  
Direct sequencing of TERT promoter in adult granulosa cell tumors  
TERT promoter (including positions 228 and 250) was PCR amplified from DNA extracted from 
all ten adult granulosa cell tumors and the recurrent adult granulosa cell tumor-derived KGN cell 
line using the following primers: 5’-CAGCGCTGCCTGAAACTC-3’ (forward) and 5’-
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GTCCTGCCCCTTCACCTT-3’ (reverse). After denaturation at 94oC for 2 minutes, DNA was 
amplified over 35 cycles (94oC 30 seconds, 62oC 30 seconds, 68oC 30 seconds), followed by a 
final extension at 68oC for 5 minutes using an MJ Research (Ramsey, MN) Tetrad. PCR products 
were bi-directionally sequenced using an ABI BigDye terminator v3.1 cycle sequencing kit 
(Applied Biosystems, Foster City, CA) and an ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA).  
Screening TERT C228T promoter mutation in extension cohort 
Allelic discrimination for TERT C228T promoter mutation in 229 primary adult granulosa cell 
tumors, 58 recurrent adult granulosa cell tumors and 22 other sex cord-stromal tumors was 
determined using a Custom TaqMan SNP Genotyping assay (Applied Biosystems, Foster City, 
CA). The sequences of the primers were as follows: 5’-CTGCCCCTTCACCTTCCA-3’ 
(forward) and 5’-GGGCCGCGGAAAGGAA-3’ (reverse). The wild-type specific probe (5’-VIC 
dye-CCCAGCCCCCTCCGG-NFQ (non-fluorescent quencher)) and mutant specific probe (5’-
FAM dye-CCAGCCCCTTCCGG-NFQ) were included in the TaqMan Genotyping Master Mix 
(2x) and reactions were performed in the QuantStudio 6 Flex Real-Time PCR System (Applied 
Biosystems, Foster City, CA) using 20 ng of DNA. After denaturation at 95oC for 10 minutes, 
DNA was amplified over 50 cycles (95oC
 
15 seconds, 60oC 90 seconds).  
TERT mRNA expression quantification in adult granulosa cell tumors 
RNA was extracted using the miRNAeasy tissue kit (Qiagen, Mississauga, ON) and quantified 
using the NanoDrop ND1000 Fluorospectrometer (ThermoFisher Scientific, Canada). cDNA 
synthesis was performed using the SuperScript IV First-Strand Synthesis System on total RNA 
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with 50 μM random hexamers (Invitrogen, Carlsbad, CA). TERT mRNA transcript expression 
was determined from the cDNA by real-time PCR in the QuantStudio 6 Flex Real-Time PCR 
System using the TERT TaqMan probe spanning exons 3 and 4 (Hs00972650_m1) with TaqMan 
Fast Advanced Master Mix (2x). The 18S (Hs03928990_g1) housekeeping gene was used for 
normalization (Applied Biosystems, Foster City, CA). The relative levels were calculated using 
the ΔΔCT method15. 
Telomere length evaluation in adult granulosa cell tumors 
Telomere length was determined using XpYp Single Telomere Length Analysis (STELA) as 
previously described16,17. Briefly, extracted DNA from all ten adult granulosa cell tumors was 
quantified by Hoechst 33258 fluorometry (Bio-Rad, Hercules, CA, USA) before dilution to 10 
ng/μl in 10 mmol/l Tris-HCl, pH 7.5. A total of 10 ng of DNA was further diluted to 250 pg/μl in 
a volume of 40 μl containing 1 μmol/l Telorette2 linker and 1 mmol/l Tris-HCl, pH 7.5. Multiple 
polymerase chain reactions (PCRs; typically 6 reactions per sample) were carried out for each 
test DNA in 10-μl volume with 250 pg of DNA, 0.5 μmol/l of the telomere-adjacent and Teltail 
primers, 75 mmol/l Tris-HCl, pH 8.8, 20 mmol/l (NH4)2SO4, 0.01% Tween-20, 1.5 mmol/l 
MgCl2, and 0.5 units of a 10:1 mixture of Taq (ABGene, Thermo Scientific) and Pwo 
polymerase (Roche Molecular Biochemicals, Burgess Hill, West Sussex, UK). The reactions 
were cycled with an MJ PTC-225 thermocycler (MJ Research, Bio-Rad). The DNA fragments 
were resolved by 0.5% Tris acetate EDTA agarose gel electrophoresis, and detected by Southern 
blot hybridization with random-primed α-33P–labelled (Perkin Elmer, Waltham, Massachusetts, 
USA) TTAGGG repeat probe together with probes to detect the 1-kb (Stratagene, Agilent 
Technologies, Santa Clara, CA, USA) and 2.5-kb (Bio-Rad) molecular weight markers. The 
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hybridized fragments were detected by phosphorimaging with a Typhoon FLA 9500 
phosphorimager (GE Healthcare). The molecular weights of the DNA fragments were calculated 
using the Phoretix 1D quantifier (Nonlinear Dynamics, Newcastle upon Tyne, UK).  
Statistical analysis  
Two-tailed Fisher exact tests were performed to compare the frequencies of TERT C228T 
mutation in adult granulosa cell tumors and other sex cord-stromal tumors, and in primary versus 
recurrent adult granulosa cell tumors. The frequency of C228T mutation in adult granulosa cell 
tumors collected from different institutions was evaluated using a two-tailed Fisher’s exact test. 
The TERT mRNA expression levels and telomere lengths of TERT mutant and TERT wild-type 
tumors were compared using a Mann-Whitney U test to determine whether TERT C228T 
promoter mutation was associated with increased TERT mRNA expression and longer telomeres, 
respectively. Overall survival, disease-specific survival and disease-free survival of adult 
granulosa cell tumors with and without TERT C228T promoter mutation were compared using 
the Kaplan-Meier method, followed by the log rank test to determine significance.  
 
Results   
TERT C228T promoter mutation is frequent in adult granulosa cell tumors 
Whole genome sequencing analysis was performed on ten adult granulosa cell tumors and 
identified a TERT C228T mutation in 50% of tumors (Figure 1A). We previously performed 
whole genome sequencing analysis on ovarian surface epithelial, including clear cell ovarian 
carcinomas, endometrioid ovarian carcinomas, and high-grade serous ovarian carcinomas. The 
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frequency of TERT promoter mutations is summarized in Table 1. We found TERT promoter 
mutations in 2 of 35 clear cell ovarian carcinomas, (5.7%), 1 of 29 endometrioid ovarian 
carcinomas (3.4%) and 0 of 59 high-grade serous ovarian carcinomas (0%)14. We did not identify 
any TERT C250T promoter mutations in adult granulosa cell tumors, thus our allelic 
discrimination analysis was performed for TERT C228T mutation in the extension cohort. The 
frequency of TERT C228T promoter mutation in the extension cohort of adult granulosa cell 
tumors and other sex cord-stromal tumors is summarized in Table 2. The C228T change was 
detected in 52 of 251 primary tumor samples (21%), with the majority occurring in adult 
granulosa cell tumors. The mutation was present in 51 of 229 primary adult granulosa cell 
tumors (22%) and 24 of 58 recurrent adult granulosa cell tumors (41%), while only in 1 of 22 
other sex cord-stromal tumors (5%). The mutation frequency between primary adult granulosa 
cell tumors and other sex cord-stromal tumors was not significant (p = 0.05448, two-tailed 
Fisher’s exact test). The C228T mutation was also present in the KGN cell line, which was 
derived from a patient with a recurrent adult granulosa cell tumor. There was no significant 
difference in TERT C228T mutation frequency among adult granulosa cell tumors collected from 
different countries (p =0.5843, two-tailed Fisher’s exact test, Figure 1B). 
TERT C228T promoter mutation is associated with elevated mRNA expression in adult 
granulosa cell tumors 
Among the ten adult granulosa cell tumors, we found that the five cases with a TERT C228T 
mutation showed a 10.8-fold increase of TERT mRNA expression as compared to the five tumors 
without a TERT promoter mutation. The majority of adult granulosa cell tumors harboring a 
TERT C228T mutation expressed higher levels of TERT mRNA compared to those with a wild-
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type TERT promoter (Figure 1C). However, the difference was not significant (p  = 0.1043, 
Mann-Whitney U test). Interestingly, we found one wild-type TERT adult granulosa cell tumor 
expressed a high level of TERT mRNA due to a copy number gain (n = 3). When this wild-type 
TERT adult granulosa cell tumor was removed from the group, TERT promoter mutants 
expressed significantly higher levels of TERT mRNA compared to those with TERT wild-type 
promoter (p = 0.01587, Mann-Whitney U test). We excluded this wild-type TERT adult 
granulosa cell tumor with the TERT copy number gain (VOA1405b) from subsequent analysis.  
Adult granulosa cell tumors with TERT C228T promoter mutation tend to have longer telomeres 
To evaluate the relationship between TERT C228T promoter mutation and telomere length, we 
assessed the XpYp telomere length in ten adult granulosa cell tumors (Figure 1D). Some of the 
tumors exhibited more heterogeneous telomere length distributions, for example VOA985c, 
VOA1173b, VOA1405b, and VOA1744b (Supplementary Figure 1A-B). Other tumours 
exhibited more homogenous telomere length distributions along with longer telomeres 
(Supplementary Figure 1A-B). TERT C228T promoter mutant adult granulosa cell tumors had 
significantly longer telomeres compared to those with wild-type TERT promoter (p = 0.0303, 
Mann-Whitney U test). Three of four tumors (VOA1617a; VOA3082b; VOA4047b) with a 
TERT mutation yield homogenous telomere length profiles that are typical of clonal growth as 
seen in the HT1080 Clone 2 control cell line and is most likely mediated by telomerase 
(Supplementary Figure 1A). The TERT promoter wild-type tumors (VOA985c; VOA1405b) that 
express TERT mRNA exhibit a wide distribution of telomere lengths and is similar to what has 
been previously described in alternative lengthening of telomeres cell lines, which use a 
recombination telomere maintenance process independent of telomerase (Supplementary Figure 
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1B). Two of the remaining three adult granulosa cell tumors with no TERT mRNA expression 
yield heterogeneous telomere lengths and resemble tumors that use the alternative lengthening of 
telomeres process. However, we interrogated the whole genome sequencing data and did not find 
any mutations in ATRX or DAXX, the two commonly mutated genes described in tumors using 
the alternative lengthening of telomeres method18,19.  
TERT C228T promoter mutation is present in recurrent adult granulosa cell tumors but absent in 
corresponding primary tumors 
Despite the numerous studies on telomerase and TERT expression in multiple cancers, it is 
poorly defined at which stage telomerase is activated in tumorigenesis. Recent reports identified 
TERT promoter mutations in early stages of melanoma20, precursor lesions of hepatocellular 
carcinomas21, and benign urothelial lesions22, suggesting that TERT promoter mutation is an 
early genetic event in oncogenesis. To determine if TERT C228T promoter mutation is an early 
mutation event in adult granulosa cell tumors, we compared the frequency of C228T mutation in 
primary (22%) and recurrent (41%) tumors and found the difference to be significant (p = 
0.003334, two-tailed Fisher’s exact test, Figure 2A). We found seven adult granulosa cell tumors 
with no TERT C228T mutation in the primary tumor but with the mutation in either the first or 
second recurrent tumor (Figure 2B). The remaining five adult granulosa cell tumors with primary 
and recurrent pairs were TERT promoter wild-type.   
 




In 186 primary adult granulosa cell tumor patients with available follow-up data, there was a 
significant difference in overall survival between patients with TERT C228T promoter mutation 
and those with TERT wild-type promoter (p = 0.00253, log rank test, Figure 3A). There was no 
significant difference in disease-specific survival (p = 0.0754, log rank test, Figure 3B) or 
disease-free survival (p = 0.705,log rank test, Figure 3C).  
 
Discussion  
In this study, we found that adult granulosa cell tumors have the highest frequency of TERT 
C228T promoter mutation among tumors that have been studied in the ovary including surface 
epithelial carcinomas and sex cord-stromal tumors. Adult granulosa cell tumors account for 
approximately 90% of sex cord-stromal tumors and are characterized by their slow, indolent 
growth23. They are thought to arise from proliferating granulosa cells of the pre-ovulatory stage, 
as the share several morphological and hormonal features, including estrogen and inhibin 
synthesis24. A single somatic missense mutation in FOXL2 (c.402C>G; pC134W) identified by 
Shah et al. was reported to be present in 86 of 89 morphologically defined adult granulosa cell 
tumors (97%)25. Subsequent validation analysis from independent research groups reported the 
high frequency and specificity of FOXL2 C402G mutation for adult granulosa cell tumors26-28. 
This mutation was also found in small number of other malignant ovarian sex cord-stromal 
tumors, but not in benign ovarian sex cord-stromal tumors, ovarian surface epithelial tumors or 
unrelated tumors25,29,30. This suggests FOXL2 C402G is pathognomonic of adult granulosa cell 
tumors and can aid in resolving diagnosis for histologically challenging cases31. FOXL2 is a 
member of the forkhead box family of transcription factors and plays a fundamental role in 
 14
ovarian folliculogenesis32. The majority of adult granulosa cell tumors are diagnosed at Stage I 
and therefore cured with surgery. However, late tumor recurrence is common and over 80% of 
patients with advanced-stage or recurrent tumors succumb to their disease33. As the FOXL2 
C402G mutation is present in essentially all adult granulosa cell tumors, it is likely that 
additional mutations drive tumor progression25. Our study is the first to use whole genome 
sequencing to provide a comprehensive catalogue of coding and non-coding genetic events in 
adult granulosa cell tumors, the most common among all sex cord-stromal tumors of the ovary. 
We compared the genomes of ten adult granulosa cell tumors with their matched normal 
genomes with the objective to identify recurrent mutations that will aid in understanding and 
improving prognosis. The high frequency of TERT C228T promoter mutation in recurrent adult 
granulosa cell tumors compared to primary adult granulosa cell tumors highlights a potential 
mechanism for clonal expansion and recurrence.  
Several studies have shown the two hot-spot TERT promoter mutations (C228T; C250T) 
generate a binding motif for ETS transcription factors and increase transcriptional activity of the 
TERT promoter11. Similarly, we observed higher TERT mRNA expression in adult granulosa cell 
tumors harboring a TERT C228T promoter mutation and TERT mutated tumors had significantly 
longer telomeres compared to TERT wild-type tumors. One TERT wild-type promoter adult 
granulosa cell tumor with an identified copy number gain expressed high levels of TERT. This 
result highlights the importance of determining both the genotype and gene expression to 
identify copy number gains or epigenetic regulation. During ovarian follicle development, 
telomerase activity is tightly regulated in a temporal and spatial pattern, where TERT expression 
is dependent on cell type and folliculogenesis stage34. Studies have reported that TERT 
expression correlates with the length of telomeres in primary granulosa cells and that small pre-
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ovulatory follicles have the highest telomerase activity with the longest telomeres35. As the 
granulosa cells undergo differentiation into luteinized granulosa cells and the follicle develops 
into the corpus luteum, there is a large decline in telomerase activity36,37. This suggests that 
telomerase plays an essential role in granulosa cell apoptosis and follicular atresia36,38. Thus, 
persistent telomerase expression in granulosa cells would result in continued survival beyond the 
necessary cell divisions and could lead to the development of an adult granulosa cell tumor. Our 
findings are consistent with a revised model recently proposed by Chiba et al., whereby cells 
harboring activating TERT promoter mutations extend their proliferative capacity39. Our results 
highlight the importance of telomerase activity in tumor development, where TERT mRNA 
expression is seen in seven of ten cases, five of which harbor the TERT C228T promoter 
mutation. 
Allelic discrimination analysis of primary and recurrent adult granulosa cell tumors indicates that 
TERT C228T promoter mutation are already present in some primary tissues, but may be late 
events which occur during adult granulosa cell tumor progression. Studies have reported TERT 
promoter mutations as an early genetic event in malignant transformation of multiple cancers20-
22. In contrast, we found that TERT C228T mutations were present in a significantly higher 
proportion of recurrent compared to primary adult granulosa cell tumors. We observed TERT 
mutations in recurrent tumors where no mutations were detected in the corresponding primary 
tumor (Figure 2B), suggesting that TERT promoter mutations were acquired during their 
progression. However, it may also be possible that TERT C228T mutation was present in the 
primary tumors at a very low frequency that was undetectable. This discordance of TERT 
mutation in paired primary and recurrent adult granulosa cell tumors suggests that these tumors 
exhibit intratumoral genetic heterogeneity. Future studies using targeted deep sequencing at the 
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TERT promoter would elucidate whether TERT mutations are present at low frequencies in 
primary tumors. It is notable that we found the TERT C228T promoter mutation in the adult 
granulosa cell tumor -derived cell line KGN. Similarly, addition of TERT expression was 
required for immortalization of the SVOG cell line that was derived from primary granulosa 
cells, suggesting the need for telomerase activity in adult granulosa cell tumors. Previous studies 
have associated TERT promoter mutations with a worse prognosis in melanoma40, glioblastoma, 
and bladder cancer patients41. In contrast, previous analysis of disease-specific survival in clear 
cell ovarian carcinoma comparing mutated TERT promoter and wild-type TERT promoter was 
not significant (p = 0.9592, log rank test)12. Although in our analysis there was a trend of worse 
disease-specific survival for TERT C228T mutant primary adult granulosa cell tumors, it was not 
significant (p = 0.0754, log rank test). Additional studies investigating all TERT promoter 
mutations, including the less common ones C250T, C242T and C243T42, would be required to 
accurately compare the prognosis of TERT promoter mutant and wild-type adult granulosa cell 
tumor patients. 
Overall, we found that TERT C228T promoter mutation was most common in adult granulosa 
cell tumors among ovarian carcinomas and sex cord-stromal tumors. Our data confirms the 
activation of telomerase in adult granulosa cell tumors via TERT C228T promoter mutation, 
although alternative telomerase activation methods in adult granulosa cell tumors may exist. Our 
results suggest that TERT activation may play a role in adult granulosa cell tumor recurrence. As 




Acknowledgements: We wish to thank all the women who generously donated the samples used 
in this study. This work is supported by the Terry Fox Research Institute Program Project grant 
#1021, the British Columbia Cancer Foundation, the Vancouver General Hospital – University of 
British Columbia Hospital Foundation (to the OvCaRe ovarian cancer research team, Vancouver) 
and Cancer Research UK (C17199/A18246). JAP is supported by the University of British 
Columbia Four-Year Doctoral Fellowship. We are grateful for the clinicians from each 
institution for patient recruitment. We would like to thank the pathologists, Drs. C. Blake Gilks, 
Friedrich Kommoss, Ralf Buzow, Hugo M. Horlings, Anthony N. Karnezis, Hector Li Chang, 
Basile Tessier-Cloutier, and Lien Hoang, for reviewing slides. We would also like to thank our 
technicians, Amy Lum and Janine Senz, for their advice.  
 
Conflict of interest: DGH and SPS are founders and shareholders of Contextual  
Genomics Inc. GA holds part time employment with Repeat Diagnostics Inc. DMB declares no 
conflict of interests other than co-authorship of a patent application based on STELA. The other 
authors declare no conflicts of interest. 
 
Statement of Authors Contributions: 
Conception and design: JAP, DRC, DGH   
Provision of study materials or patients: AF, HMH, SY, EO, SK, FK, DGH 
Collection and assembly of data: JAP, DRC, ZX, GA, DMB, AF, HMH, SY, SK 
Data analysis and interpretation: JAP, DRC, YW, GA, DMB 
Manuscript writing: JAP, DRC, GA, DGH 
Final approval of manuscript: All authors 
 18
References: 
1  Akincilar, S. C., Unal, B. & Tergaonkar, V. Reactivation of telomerase in cancer. Cell 
Mol Life Sci 2016;73:659-1670. 
2  Jafri, M. A., Ansari, S. A., Alqahtani, M. H. et al. Roles of telomeres and telomerase in 
cancer, and advances in telomerase-targeted therapies. Genome Med 2016;8:69. 
3  Zhang, Q., Kim, N. K. & Feigon, J. Architecture of human telomerase RNA. Proc Natl 
Acad Sci U S A 2016;108:20325-20332. 
4  Chiba, K., Johnson, J. Z., Vogan, J. M. et al. Cancer-associated TERT promoter 
mutations abrogate telomerase silencing. Elife 2015;4:7918. 
5  Kim NW, P. M., Prowse K.R., Harley C.B. et al. Specific association of human 
telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015. 
6  Shay, J. W. Are short telomeres predictive of advanced cancer? Cancer Discov 
2013;3:1096-1098. 
7  Cesare, A. J. & Reddel, R. R. Alternative lengthening of telomeres: models, mechanisms 
and implications. Nat Rev Genet 2010;11:319-330. 
8  Horn, S., Figl, A., Rachakonda, P. S. et al. TERT Promoter Mutations in Familial and 
Sporadic Melanoma. Science 2013;339:959. 
9  Huang, F. W., Hodis, E., Xu, M. J. et al. Highly recurrent TERT promoter mutations in 
human melanoma. Science 2013;339:957-959. 
10  Vinagre, J., Almeida, A., Populo, H. et al. Frequency of TERT promoter mutations in 
human cancers. Nat Commun 2013;4:2185. 
11  Huang, F. W., Bielski, C. M., Rinne, M. L. et al. TERT promoter mutations and 
monoallelic activation of TERT in cancer. Oncogenesis 2015;4:e176.  
 19
12  Wu, R. C., Ayhan, A., Maeda, D. et al. Frequent somatic mutations of the telomerase 
reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major 
types of gynaecological malignancy. J Pathol 2014;232:473-481. 
13  McConechy, M. K., Farkkila, A., Horlings, H. M. et al. Molecularly Defined Adult 
Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. J Natl Cancer Inst 
2016;108:djw134. 
14  Wang, Y. K., Bashashati, A., Anglesio, M. S. et al. Genomic consequences of aberrant 
DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet 2017;49:856-865. 
15  Livak, K. J. & Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real- 
Time Quantitative PCR and the 2−ΔΔCT Method. Methods 2001;25:402-408. 
16  Lin, T. T., Letsolo, B. T., Jones, R. E. et al. Telomere dysfunction and fusion during the 
progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood 
2010;116:1899-1907. 
17  Roger, L., Jones, R. E., Heppel, N. H. et al. Extensive telomere erosion in the initiation of 
colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst 
2013;105:1202-1211. 
18 Flynn, R. L., Cox, K. E., Jeitany, M. et al. Alternative lengthening of telomeres renders 
cancer cells hypersensitive to ATR inhibitors. Science 2015;347:273. 
19  Heaphy, C. M., de Wilde, R. F., Jiao, Y. et al. Altered Telomeres in Tumors with ATRX 
and DAXX Mutations. Science 2011;333:425. 
20  Shain, A. H., Yeh, I., Kovalyshyn, I. et al. The Genetic Evolution of Melanoma from 
Precursor Lesions. N Engl J Med 2015;373:1926-1936. 
21  Nault, J. C., Mallet, M., Pilati, C. et al. High frequency of telomerase reversetranscriptase 
 20
promoter somatic mutations in hepatocellular carcinoma and preneoplastic 
lesions. Nat Commun 2013;4:2218. 
22  Cheng, L., Davidson, D. D., Wang, M. et al. Telomerase reverse transcriptase (TERT) 
promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a 
subpopulation of inverted papilloma with immortalizing genetic change. Histopathology 
2016;69:107-113. 
23  Fuller, P. J., Leung, D. & Chu, S. Genetics and genomics of ovarian sex cord-stromal 
tumors. Clin Genet 2017;91:285-291. 
24  Rosario, R., Cohen, P. A. & Shelling, A. N. The role of FOXL2 in the pathogenesis of 
adult ovarian granulosa cell tumours. Gynecol Oncol 2014;133:382-387. 
25  Shah, S. P., Köbel, M., Senz, J. et al. Mutation of FOXL2 in Granulosa-Cell Tumors of 
the Ovary. N Engl J Med 2009;360:2719-2729. 
26 Kim, M. S., Hur, S. Y., Yoo, N. J. et al. Mutational analysis of FOXL2 codon 134 in 
granulosa cell tumour of ovary and other human cancers. J Pathol 2010;221:147-152. 
27 Kim, T., Sung, C. O., Song, S. Y. et al. FOXL2 mutation in granulosa-cell tumours of the 
ovary. Histopathology 2010;56:408-410. 
28 Jamieson, S., Butzow, R., Andersson, N. et al. The FOXL2 C134W mutation is 
characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 2010;23:1477-
1485. 
29 Schrader, K. A., Gorbatcheva, B., Senz, J. et al. The specificity of the FOXL2 c.402C>G 
somatic mutation: a survey of solid tumors. PLoS One 2009;4:e7988. 
30 Al-Agha, O. M., Huwait, H. F., Chow, C. et al. FOXL2 is a sensitive and specific marker 
for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011;35, 484-494. 
 21
31 Kobel, M., Gilks, C. B. & Huntsman, D. G. Adult-type granulosa cell tumors and FOXL2 
mutation. Cancer Res 2009;69:9160-9162. 
32 Leung, D. T., Fuller, P. J. & Chu, S. Impact of FOXL2 mutations on signaling in ovarian 
granulosa cell tumors. Int J Biochem Cell Biol 2016;72:51-54. 
33 Jamieson, S. & Fuller, P. J. Molecular pathogenesis of granulosa cell tumors of the ovary. 
Endocr Rev 2012;33:109-144. 
34 Liu, J. P. & Li, H. Telomerase in the ovary. Reproduction 2010;140:215-222. 
35 Russo, V., Berardinelli, P., Martelli, A. et al. Expression of Telomerase Reverse 
Transcriptase Subunit (TERT) and Telomere Sizing in Pig Ovarian Follicles. J Histochem 
Cytochem 2006;54:443-455. 
36 Yamagata, Y., Nakamura, Y., Umayahara, K. et al. Changes in Telomerase Activity in 
Experimentally Induced Atretic Follicles of Immature Rats. Endocr J 2002;49:589-595. 
37 Kossowska-Tomaszczuk, K., De Geyter, C., De Geyter, M. et al. The multipotency of 
luteinizing granulosa cells collected from mature ovarian follicles. Stem Cells 
2009;27:210-219. 
38 Lavranos, T. C., Mathis Jm Fau - Latham, S. E., Latham Se Fau - Kalionis, B. et al. 
Evidence for ovarian granulosa stem cells: telomerase activity and localization of the 
telomerase ribonucleic acid component in bovine ovarian follicles. Biol Reprod 
1999;2:358-366 
39 Chiba, K., Lorbeer, F. K., Shain, A. H. et al. Mutations in the promoter of the telomerase 
gene TERT contribute to tumorigenesis by a two-step mechanism. Science 
2017;6358:1416-1420. 
40 Nagore, E., Heidenreich, B., Rachakonda, S. et al. TERT promoter mutations in 
 22
melanoma survival. Int J Cancer 2016;139:75-84. 
41 Killela, P. J., Reitman, Z. J., Jiao, Y. et al. TERT promoter mutations occur frequently in 
gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc 
Natl Acad Sci U S A. 2013;110:6021-6026. 
42 Scott, G. A., Laughlin, T. S. & Rothberg, P. G. Mutations of the TERT promoter are 




Figure 1. (A) TERT promoter mutation in adult granulosa cell tumors. Shown is the schematic 
diagram of the TERT promoter region, representative chromatograms of the two hot-spot 
mutations (C228T; C250T). (B) Mutation status of TERT C228T promoter in adult granulosa cell 
tumors separated by the country in which they were collected from: dark grey, TERT C228T 
mutated promoter; light grey, TERT wild-type promoter (C) Adult granulosa cell tumors with 
mutated TERT promoter have increased expression of TERT mRNA; black horizontal bar, mean 
(D) Comparison of XpYp STELA telomere length mean between adult granulosa cell tumors 
with and without TERT promoter mutation; black horizontal bar, group mean 
 
Figure 2. (A) Mutation status of TERT C228T promoter in primary and recurrent adult granulosa 
cell tumors: dark grey, TERT C228T mutated promoter; light grey, TERT wild-type promoter. 
(B) An example of acquired TERT C228T promoter mutations in seven adult granulosa cell 
tumors with primary and recurrent tumour pairs: dark grey, TERT C228T mutated promoter; 
light grey, TERT wild-type promoter 
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Figure 3. Kaplan-Meier survival curves of adult granulosa cell tumor patients (A) Overall 
survival in patients with TERT C228T promoter mutation is worse than patients with wild-type 
TERT promoter (p = 0.00253, log rank test) (b) Disease-specific survival in patients with TERT 
C228T promoter mutation is similar to patients with wild-type TERT promoter (p = 0.0754, log 
rank test) (c) Disease-free survival in patients with TERT C228T promoter mutation is similar to 












Table 1. Prevalence of TERT C228T and C250T promoter mutations in ovarian cancer 
C228T C250T Mutated/Total % 
Ovarian cancer    
     Adult granulosa cell tumor 5 0 5/10 50 
     Clear cell ovarian carcinoma 1 1 2/35 5.7 
     Endometrioid ovarian carcinoma 1 0 1/29 3.4 
     High-grade serous ovarian carcinoma 0 0 0/59 0 
 
Table 2. Prevalence of TERT C228T promoter mutation in ovarian sex cord-stromal tumors  
Mutated/Total % 
Ovarian sex cord-stromal tumor 
     Primary adult granulosa cell tumor 51/229 22 
     Recurrent adult granulosa cell tumor 24/58 41 
     Adult granulosa cell tumor KGN cell line 1/1 100 
     Sertoli-Leydig cell tumor 1/5 20 
     Fibroma/Thecoma 0/14 0 
     Gynandroblastoma  0/1 0 
     Unclassified 0/2 0 
 
 
